Image via Wikipedia
Summit at Lake Como with 100 European stem cell experts.
At the summit, 16 research teams part of the Neurostemcell consortium that have been working for months on finding treatments for Parkinson’s and Huntington’s disease met. The network, coordinated by Elena Cattaneo, Director of Unistem, the interdepartmental stem cell research centre of the University of Milan, met on April 1 in Bellagio, on the shores of Lake Como for their first annual meeting.
“The meeting is an opportunity to discuss the results obtained until now and to refine our methods,” explained Cattaneo, who pointed out the objective of
Piece by missing piece, scientists at the Keck School of Medicine of USC are deciphering the powerful gene regulatory circuit that maintains and controls the potential of embryonic stem cells (ESCs) to form any type of cell in the body.
Recent findings by Provost Professor Andrew McMahon, director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and Qilong Ying, associate professor of cell and neurobiology, underscore the essential role of basic science in paving the way for future medical breakthroughs.
McMahon and Ying are in pursuit of the ways in which the intricate
Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson’s disease, Alzheimer’s disease and other neurological disorders.
The bulk of neuron production in the central nervous system takes place before birth, and comes to a halt by birth. But scientists have identified specific regions in the core of the brain that retain stem cells into adulthood and continue to produce new
According to the European Patent Office, there will be no patents in Europe for embryonic stem cells. The board decided to fully uphold a sentence from June by a select committee regarding a request for a patent made by the Wisconsin Alumni Research Foundation, based at the University where James Thompson, the scientist who discovered stem cells, works. “European patent law prohibits the application of patents to stem cell cultures whose preparation necessarily implicates the destruction of human embryos.”
Image via Wikipedia
Adult stem cells and their more committed kin, progenitor cells, are prized by medical researchers for their ability to produce different types of specialised cells. The potential of using these cells to repair or replace damaged tissue holds great promise for cancer therapies and regenerative medicine. However, the question that must first be answered is what determines the ultimate fate of a stem or progenitor cell? A team of researchers led by Berkeley Lab’s Mark LaBarge and Mina Bissell appear to be well on the road to finding out.
Working with unique microenvironment microarrays (MEArrays) of their own